[Gastric adenocarcinoma in young adults; comparative study with older patients]. / Adenocarcinoma gástrico en adultos jóvenes; estudio comparativo con pacientes mayores.

BACKGROUND: Gastric adenocarcinoma (GA) has been considered a disease of elderly age and has been rarely reported in patients younger than 35 years of age. The aim of thisΩ demographic, clinicopathological and prognosis of gastric cancer in young patients and to compare their features with the behavior in elder adults. METHODS: Between 1993 and 2008, 1536 patients with GA were enrolled in a retrospective database. Clinical and pathologic features of thirty patients aged 35 years or less (young group) were compared with those of 458 aged 75 years or more (elder group). RESULTS: Mean patient age was 31 and 80-years old in the young and elder groups, respectively, with a predominance of females in the last group (61%). Lauren diffuse type carcinoma was more frequent in people younger than 35 years (70%) than in older patients (17.4%). Main symptoms were dyspepsia (40%) and hemorrhage (20%). The most common T stage in young and elder patients was T3 (52.9% and 56.7% respectively). Surgical resection was performed in 68% of cases and the rest received only systemic chemotherapy. CONCLUSION: Gastric adenocarcinoma is rare in young patients and most cases presented at advanced clinical stage similar to elderly patients, so the prognosis in both age groups is poor. For this reason is important to be aware of alarm symptoms and risk factors in order to perform an early endoscopic diagnosis and a treatment with curative intent.

Altered expression of the lymphocyte activation antigen CD30 in active celiac disease.

Interleukin (IL)-15 and CD30 may be associated with the ongoing intestinal immunologic activation in celiac disease (CD). We studied duodenal biopsies and blood samples of patients with active CD (Cel) and controls in order to determine the regulatory role proposed for CD30(+) T cells in this Th1-driven disease and the potential influences of IL-15 on CD30 expression. We detected that a CD30(+) T-cell subpopulation persists longer in Cel after a 5 day incubation with anti-CD3 antibody than in controls (p = 0.0063). CD30 upregulation by IL-15 in T blasts was greater in Cel than in controls (p = 0.0062). At the mucosal compartment, the CD30 antigen was examined by immunohistochemistry and quantified on isolated lamina propria (LP) and epithelial T cells by flow cytometry. For Cel and controls, similar mean percentages of CD3(+)CD30(+) intraepithelial T cells (5.88 vs. 5.51, p = ns) and LP T cells (7.38 vs. 7.49, p = ns) were observed at baseline and after in vitro gliadin challenge of duodenal biopsy samples. Our study demonstrates the occurrence of potentially important alterations of the immune response at the peripheral compartment. Our findings also allow us to speculate that a negative effect of soluble mediators at the mucosal compartment might counteract the latent influence of IL-15 on CD30 expression precluding a more severe course of active CD.

Oxycodone: a pharmacological and clinical review.

Oxycodone is a semi-synthetic opioid with an agonist activity on mu, kappa and delta receptors. Equivalence with regard to morphine is 1:2. Its effect commences one hour after administration and lasts for 12 h in the controlled-release formulation. Plasma halflife is 3-5 h (half that of morphine) and stable plasma levels are reached within 24 h (2-7 days for morphine). Oral bioavailability ranges from 60 to 87%, and plasma protein binding is 45%. Most of the drug is metabolised in the liver, while the rest is excreted by the kidney along with its metabolites. The two main metabolites are oxymorphone--which is also a very potent analgesic--and noroxycodone, a weak analgesic. Oxycodone metabolism is more predictable than that of morphine, and therefore titration is easier. Oxycodone has the same mechanism of action as other opioids: binding to a receptor, inhibition of adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability. These mechanisms also play a part in the onset of dependence and tolerance. The clinical efficacy of oxycodone is similar to that of morphine, with a ratio of 1/1.5-2 for the treatment of cancer pain. Long-term administration may be associated with less toxicity in comparison with morphine. In the future, both opioids could be used simultaneously at low doses to reduce toxicity. It does not appear that there are any differences between immediate and slow-release oxycodone, except their half-life is 3-4 h, and 12 h, respectively. In Spain, controlled-release oxycodone (OxyContin) is marketed as 10-, 20-, 40- or 80-mg tablets for b.i.d. administration. Tablets must be taken whole and must not be broken, chewed or crushed. There is no food interference. The initial dose is 10 mg b.i.d. for new treatments and no dose reduction is needed in the elderly or in cases of moderate hepatic or renal failure. Immediate-release oxycodone (OxyNorm) is also available in capsules and oral solution. Side effects are those common to opioids: mainly nausea, constipation and drowsiness. Vomiting, pruritus and dizziness are less common. The intensity of these side effects tends to decrease over the course of time. Oxycodone causes somewhat less nausea, hallucinations and pruritus than morphine.

Enfermedad celiaca. Nuevas perspectivas terapeuticas basadas en un mejor conocimiento de su patogenia molecular. / Celiac disease. New therapeutic alternatives based on a better knowledge of molecular pathogenesis

La enfermedad celiaca (EC) es una patologia gastrointestinalcronica de tipo autoinmune desencadenadapor un antigeno exogeno conocido (el gluten). Estafuertemente asociada al sistema HLA, aunque otrosfactores geneticos, ambientales e inmunologicos, aun nocompletamente identificados, determinarian el momentoy forma de presentacion. La respuesta inmuneen la mucosa intestinal frente a ciertos peptidos derivados de gliadinas es caracterizada por una fuerte respuestade tipo TH1 (con predominio de IFN secretadopor linfocitos T específicos), la que es probablementeprecedida por una respuesta inmune innata, mediadafundamentalmente por IL-15. La dieta estricta librede gluten es la forma mas eficaz de revertir las alteracionesde la mucosa intestinal y la sintomatologia. Sin embargo, las transgresiones y el bajo cumplimientode la dieta han conducido a formular nuevas estrategias terapeuticas que se discuten en esta revision.

Coeliac disease is a chronic autoimmune-like gastrointestinal disorder triggered by a known exogenous antigen (gluten). The disease is strongly linked to the HLA system, though other genetic, environmental and immunologic factors, may determine the type and timing of presentation. The immune response within the intestinal mucosa is characterized by a well defined TH1 response, where IFNgamma secreted by specific T cells is the predominant cytokine, as well as an innate immune response to certain gluten-derived peptides, mediated by IL-15. The strict gluten-exclusion diet is the best way of reversing both the symptoms and the histological changes in the intestinal mucosa. However, the frequency of transgressions and a low dietary compliance had led to the description of new therapeutic alternatives discussed in this review.

Enfermedad celiaca. Nuevas perspectivas terapeuticas basadas en un mejor conocimiento de su patogenia molecular. / Celiac disease. New therapeutic alternatives based on a better knowledge of molecular pathogenesis

La enfermedad celiaca (EC) es una patologia gastrointestinalcronica de tipo autoinmune desencadenadapor un antigeno exogeno conocido (el gluten). Estafuertemente asociada al sistema HLA, aunque otrosfactores geneticos, ambientales e inmunologicos, aun nocompletamente identificados, determinarian el momentoy forma de presentacion. La respuesta inmuneen la mucosa intestinal frente a ciertos peptidos derivados de gliadinas es caracterizada por una fuerte respuestade tipo TH1 (con predominio de IFN secretadopor linfocitos T específicos), la que es probablementeprecedida por una respuesta inmune innata, mediadafundamentalmente por IL-15. La dieta estricta librede gluten es la forma mas eficaz de revertir las alteracionesde la mucosa intestinal y la sintomatologia. Sin embargo, las transgresiones y el bajo cumplimientode la dieta han conducido a formular nuevas estrategias terapeuticas que se discuten en esta revision.(AU)

Coeliac disease is a chronic autoimmune-like gastrointestinal disorder triggered by a known exogenous antigen (gluten). The disease is strongly linked to the HLA system, though other genetic, environmental and immunologic factors, may determine the type and timing of presentation. The immune response within the intestinal mucosa is characterized by a well defined TH1 response, where IFNgamma secreted by specific T cells is the predominant cytokine, as well as an innate immune response to certain gluten-derived peptides, mediated by IL-15. The strict gluten-exclusion diet is the best way of reversing both the symptoms and the histological changes in the intestinal mucosa. However, the frequency of transgressions and a low dietary compliance had led to the description of new therapeutic alternatives discussed in this review.(AU)